Pharmax opens generics plant in Dubai

Wockhardt Dubai
UAE-based Pharmax has begun production at a new facility in Dubai shortly after India's Wockhardt recently opened this plant there. (Wockhardt)

After a three-year project, Pharmax Pharmaceuticals is now producing generic drugs in a small but new plant in Dubai.

The UAE-based drugmaker has opened the AED125 million ($34 million) facility located in Dubai Science Park, reported the Arabian Business, citing a company statement. The facility, which has an annual capacity of more than 200 million tablet and capsule dosage forms, has 40 employees and intends to add another 15 in the next few months.

The project is a joint venture of UAE drug distributor Al Ittihad Drug Store and Cooper Pharma and Bottu Pharmaceuticals, both based in Morocco, according to Arabian Business. The company will make a wide variety of drugs including medications for cardiovascular diseases, psychiatric and neurological disorders, gastroenterological diseases, and diabetes.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Wockhardt builds $40M plant in Dubai to produce ‘superbug’ fighters

The opening of the Pharmax plant comes just weeks after India’s Wockhardt announced it had inaugurated a 10,000-square-meter (107,639-square-foot) facility in the Jebel Ali Free Zone in Dubai to make antibiotics. The manufacturing and R&D project includes production of aseptic dry powder and filling, as well as warehousing, product testing and product stability.

It is being built to produce the novel antibiotics that Wockhardt is developing for sale globally. The company said it has five novel drugs that the FDA has granted Qualified Infectious Disease Program (QIDP) status.

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.